Break the GPO Ceiling: Get the Guide
  • Cutting-Edge
    Clinical Trials

Every therapy, drug or approach that is in place today to treat cancer had its start in a clinical trial. American Oncology Partner practices bring innovative treatment options to patients, close to home. We offer clinical trial options to patients across several locations within AON’s network of oncology practices.

Clinical Trial researcher placing test tube in holder.

Why participate in clinical trials?

Clinical trials are designed to evaluate the effectiveness of new treatment interventions. The objective of these clinical trials is to test new therapies in patients who have cancer. Patients participate in clinical trials for several reasons, including:

  • The potential to benefit from a new drug or treatment procedure
  • Improved management of symptoms resulting from treatment of cancer
  • The opportunity to directly contribute to improving the understanding of how to treat a cancer and ultimately, benefit other patients

Patients who participate in clinical trials receive either a promising new treatment or the best available conventional treatment. If a new treatment option is proven to work, patients who are participating in the clinical trial will be among the first to benefit. While there is no guarantee that any treatment will be successful, clinical trials have been proven to offer some of the most effective cancer treatments currently available today.

Talk to your doctor to discuss your clinical trial options.

Search for a Clinical Trial

Cancer Type

Practice

Line of Therapy

20180146

Prostate Cancer

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

MORE DETAILS
221530 (JADE)

Head and Neck Cancer

Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy After Chemoradiation in Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

MORE DETAILS
224317 (DREAMM-15)

Multiple Myeloma

A Phase 2, Multicenter, Open Label, Non-randomized Study to Evaluate the Efficacy and Safety of Extended Dosing of Belantamab Mafodotin in Different Combinations With Standard of Care Regimens in Participants With Relapsed-refractory Multiple Myeloma (DREAMM-15)

MORE DETAILS
25-092-NCP

Solid Tumors

Bespoke Pan Cancer Molecular Residual Disease (MRD) Detection and Monitoring in any cancer

MORE DETAILS
25-092-NCP BESPOKE

Biliary Cancer, Bladder Cancer, Brain Cancer, Breast Cancer, Colon and Rectal Cancer, CLL/SLL, Gastroesophageal Cancer, Gastric, GIST, Liver Cancer, Pancreatic Cancer, Testicular, Solid Tumors, Head and Neck Cancer, Hematology and Blood Disorders, Kidney Cancer, Leukemia, Lymphoma, Lung Cancer, Multiple Myeloma, Melanoma, Ovarian and Endometrial Cancer, Sarcoma, Prostate Cancer

Bespoke Pan-Cancer

MORE DETAILS
306293 ~ StrateGIST

Sarcoma, GIST

A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) Versus Imatinib in Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)

MORE DETAILS
61186372NS2012 COPERNICUS

Lung Cancer

A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

MORE DETAILS
64007957MMY3005 (MajesTEC-7)

Multiple Myeloma

A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy

MORE DETAILS
75276617AML3001

Leukemia

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy

MORE DETAILS

We use cookies and similar technologies to operate our website. We also use cookies to improve your experience, analyze website performance, and provide personalized content, including through our analytics and advertising partners. You can choose which optional cookies to allow by selecting Cookie Preferences. Essential cookies are always enabled because they are necessary for the website to function properly. By selecting Accept All, you consent to our use of optional cookies as described in our Website Privacy & Cookie Notice

We use required cookies to operate the site. With your consent, we use optional cookies and similar technologies for enhanced features, analytics, and advertising.